TCGA-AC-A5EH-01A-11R-A28M-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 17
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- OXIDATIVE_PHOSPHORYLATION+0.410
- HYPOXIA+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- TNFA_SIGNALING_VIA_NFKB+0.350
- GLYCOLYSIS+0.330
- APICAL_JUNCTION+0.290
- APOPTOSIS+0.280
- HEDGEHOG_SIGNALING+0.280
Top 10 suppressed
- E2F_TARGETS-0.220
- PROTEIN_SECRETION-0.220
- INTERFERON_ALPHA_RESPONSE-0.170
- G2M_CHECKPOINT-0.160
- DNA_REPAIR-0.150
- UV_RESPONSE_DN-0.130
- WNT_BETA_CATENIN_SIGNALING-0.110
- MYC_TARGETS_V1-0.100
- ESTROGEN_RESPONSE_EARLY-0.080
- SPERMATOGENESIS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-39-5039-01A-01R-1443-07 | — | cohortSQ1 | 0.814 |
| 2 | SRR8518423 | — | C | 0.798 |
| 3 | SRR1465917 | GTEX | — | 0.793 |
| 4 | AUR-AER6-TTM1-A-1-1-R-A742-41 | — | C | 0.790 |
| 5 | TCGA-A2-A04W-01A-31R-A115-07 | — | C | 0.788 |
| 6 | MDT-AP-1256 | Med | Medulloblastoma | 0.784 |
| 7 | SRR35579831 | — | C | 0.778 |
| 8 | BSR_06_0059_A2_S99 | — | F | 0.778 |
| 9 | 5467227e-26db-4241-9b21-0dd8ee39fcee | — | — | 0.775 |
| 10 | d25af392-21ad-4aa6-8669-34656bf71af5 | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.510 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |